CRA 028129

Drug Profile

CRA 028129

Alternative Names: Cathepsin S inhibitor (psoriasis) - Celera Genomics; CRA-028129

Latest Information Update: 22 Mar 2010

Price : $50

At a glance

  • Originator Bayer Schering Pharma; Celera Genomics Group
  • Class Antipsoriatics
  • Mechanism of Action Cathepsin S inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Psoriasis

Most Recent Events

  • 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
  • 27 Jun 2006 Schering AG has acquired CRA 028129 from Celera Genomics
  • 20 Sep 2005 Phase-I clinical trials in Psoriasis in New Zealand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top